Pub Date : 2024-10-15DOI: 10.3899/jrheum.2024-0881
Gretchen Santana Cepero,John E McKinnon,Kathleen Maksimowicz-McKinnon
In the article entitled "Prevalence, Predictors, and Prognosis of Serious Infections in Takayasu Arteritis: A Cohort Study" by Misra and colleagues in this issue of The Journal of Rheumatology, the authors examine the incidence of serious infections in a Takayasu arteritis (TA) patient cohort; analyze associated demographic, clinical, angiographic, and treatment-related factors; and evaluate their impact on serious infections and mortality in TA.1 They found that serious infections in patients with TA were prevalent, occurring in one-sixth of their cohort, with pneumonia (38%) and tuberculosis (TB; 24%) as the most common infections identified.1.
{"title":"Infections in Vasculitis: Can We Create an Epidemic of Change?","authors":"Gretchen Santana Cepero,John E McKinnon,Kathleen Maksimowicz-McKinnon","doi":"10.3899/jrheum.2024-0881","DOIUrl":"https://doi.org/10.3899/jrheum.2024-0881","url":null,"abstract":"In the article entitled \"Prevalence, Predictors, and Prognosis of Serious Infections in Takayasu Arteritis: A Cohort Study\" by Misra and colleagues in this issue of The Journal of Rheumatology, the authors examine the incidence of serious infections in a Takayasu arteritis (TA) patient cohort; analyze associated demographic, clinical, angiographic, and treatment-related factors; and evaluate their impact on serious infections and mortality in TA.1 They found that serious infections in patients with TA were prevalent, occurring in one-sixth of their cohort, with pneumonia (38%) and tuberculosis (TB; 24%) as the most common infections identified.1.","PeriodicalId":501812,"journal":{"name":"The Journal of Rheumatology","volume":"44 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142443774","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-10-15DOI: 10.3899/jrheum.2024-0223
Victoria Navarro-Compán,Martin Rudwaleit,Maureen Dubreuil,Marina Magrey,Helena Marzo-Ortega,Philip J Mease,Jessica A Walsh,Maxime Dougados,Christine de la Loge,Carmen Fleurinck,Ute Massow,Thomas Vaux,Vanessa Taieb,Atul Deodhar
OBJECTIVETo assess the effect of bimekizumab on pain, morning stiffness, and fatigue in patients with nonradiographic and radiographic axial spondyloarthritis (axSpA) in the phase III BE MOBILE studies (ClinicalTrials.gov: NCT03928704 and NCT03928743).METHODSPatients were randomized to bimekizumab 160 mg or placebo every 4 weeks; and all patients received bimekizumab from week 16. Patients reported spinal pain, peripheral pain, morning stiffness, and fatigue to week 52. Total and nocturnal spinal pain were each assessed on a 0-10 numerical rating scale (NRS). Individual Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) items (0-10-point NRS) assessed peripheral arthritis pain (question [Q] 3), enthesitis pain/discomfort (Q4), morning stiffness (mean of Q5 and Q6), and fatigue (Q1). Functional Assessment of Chronic Illness Therapy Fatigue subscale score (FACIT-Fatigue) is also reported.RESULTSAt week 16, bimekizumab-treated patients reported lower mean nocturnal spinal pain, total spinal pain, and BASDAI scores (nominal except for nocturnal spinal pain; all P ≤ 0.001), as well as higher FACIT-Fatigue scores (nominal P < 0.05) vs placebo, indicating improved symptom levels. Improvements continued to week 52 in continuous bimekizumab-treated patients and in placebo-bimekizumab switchers. A higher proportion of bimekizumab- vs placebo-randomized patients achieved increasingly stringent thresholds for low spinal and peripheral pain at week 16; this was sustained or improved at week 52. Results were similar for morning stiffness and fatigue. At week 52, over half of patients were considered FACIT-Fatigue responders (≥ 8-point increase in score).CONCLUSIONBimekizumab treatment led to rapid improvements in levels of pain and morning stiffness. Substantial improvements were seen in all domains across the full disease spectrum of axSpA and continued to week 52.
目的评估在 BE MOBILE III 期研究（ClinicalTrials.gov：NCT03928704 和 NCT03928743）中，bimekizumab 对非放射性和放射性轴性脊柱关节炎 (axSpA) 患者的疼痛、晨僵和疲劳的影响。方法患者被随机分配到 bimekizumab 160 毫克或安慰剂，每 4 周一次；所有患者从第 16 周开始接受 bimekizumab 治疗。截至第52周，患者报告了脊柱疼痛、外周疼痛、晨僵和疲劳情况。总脊柱疼痛和夜间脊柱疼痛均采用 0-10 数字评分量表（NRS）进行评估。巴斯强直性脊柱炎疾病活动指数（BASDAI）的各个项目（0-10 分 NRS）评估了外周关节炎疼痛（问题 [Q] 3）、关节炎疼痛/不适（Q4）、晨僵（Q5 和 Q6 的平均值）和疲劳（Q1）。结果第16周时，与安慰剂相比，bimekizumab治疗患者的夜间脊柱疼痛、脊柱总疼痛和BASDAI平均评分较低（除夜间脊柱疼痛外均为标称值；均P≤0.001），FACIT-疲劳评分较高（标称值P＜0.05），表明症状水平有所改善。持续接受比美珠单抗治疗的患者和安慰剂-比美珠单抗转换者的症状改善持续到第52周。在第16周时，比美单抗与安慰剂随机治疗的患者中，有更高比例的患者达到了越来越严格的低脊柱和外周疼痛阈值；这种情况在第52周时得到了维持或改善。晨僵和疲劳的结果类似。第52周时，超过一半的患者被认为是FACIT-疲劳应答者（得分增加≥8分）。在axSpA的整个疾病谱中，所有领域都出现了实质性改善，并一直持续到第52周。
{"title":"Improved Pain, Morning Stiffness, and Fatigue With Bimekizumab in Axial Spondyloarthritis: Results From the Phase III BE MOBILE Studies.","authors":"Victoria Navarro-Compán,Martin Rudwaleit,Maureen Dubreuil,Marina Magrey,Helena Marzo-Ortega,Philip J Mease,Jessica A Walsh,Maxime Dougados,Christine de la Loge,Carmen Fleurinck,Ute Massow,Thomas Vaux,Vanessa Taieb,Atul Deodhar","doi":"10.3899/jrheum.2024-0223","DOIUrl":"https://doi.org/10.3899/jrheum.2024-0223","url":null,"abstract":"OBJECTIVETo assess the effect of bimekizumab on pain, morning stiffness, and fatigue in patients with nonradiographic and radiographic axial spondyloarthritis (axSpA) in the phase III BE MOBILE studies (ClinicalTrials.gov: NCT03928704 and NCT03928743).METHODSPatients were randomized to bimekizumab 160 mg or placebo every 4 weeks; and all patients received bimekizumab from week 16. Patients reported spinal pain, peripheral pain, morning stiffness, and fatigue to week 52. Total and nocturnal spinal pain were each assessed on a 0-10 numerical rating scale (NRS). Individual Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) items (0-10-point NRS) assessed peripheral arthritis pain (question [Q] 3), enthesitis pain/discomfort (Q4), morning stiffness (mean of Q5 and Q6), and fatigue (Q1). Functional Assessment of Chronic Illness Therapy Fatigue subscale score (FACIT-Fatigue) is also reported.RESULTSAt week 16, bimekizumab-treated patients reported lower mean nocturnal spinal pain, total spinal pain, and BASDAI scores (nominal except for nocturnal spinal pain; all P ≤ 0.001), as well as higher FACIT-Fatigue scores (nominal P < 0.05) vs placebo, indicating improved symptom levels. Improvements continued to week 52 in continuous bimekizumab-treated patients and in placebo-bimekizumab switchers. A higher proportion of bimekizumab- vs placebo-randomized patients achieved increasingly stringent thresholds for low spinal and peripheral pain at week 16; this was sustained or improved at week 52. Results were similar for morning stiffness and fatigue. At week 52, over half of patients were considered FACIT-Fatigue responders (≥ 8-point increase in score).CONCLUSIONBimekizumab treatment led to rapid improvements in levels of pain and morning stiffness. Substantial improvements were seen in all domains across the full disease spectrum of axSpA and continued to week 52.","PeriodicalId":501812,"journal":{"name":"The Journal of Rheumatology","volume":"89 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142443772","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-05-16DOI: 10.3899/jrheum.2023-0698.C1
Jennifer Weinstein, S. Rosero, J. Seabury, Anika Varma, C. Engebrecht, S. Khosa, J. Heatwole, N. Dilek, Aaron Kaat, Lynne Kennedy Matallana, C. Heatwole
J Rheumatol 2024; doi: 10.3899/jrheum.2023-0698 Lynne Kennedy Matallana, MS, was missing from the author byline and footnotes. Her affiliation is National Fibromyalgia Association, Newport Beach, California, USA. She declares no conflicts of interest relevant to the article. This correction applies only to the February 15 2024 First Release. The correct author byline and footnotes appear in the print and online issues.
{"title":"Patient-Reported Impact of Symptoms in Fibromyalgia (PRISM-FM).","authors":"Jennifer Weinstein, S. Rosero, J. Seabury, Anika Varma, C. Engebrecht, S. Khosa, J. Heatwole, N. Dilek, Aaron Kaat, Lynne Kennedy Matallana, C. Heatwole","doi":"10.3899/jrheum.2023-0698.C1","DOIUrl":"https://doi.org/10.3899/jrheum.2023-0698.C1","url":null,"abstract":"J Rheumatol 2024; doi: 10.3899/jrheum.2023-0698 Lynne Kennedy Matallana, MS, was missing from the author byline and footnotes. Her affiliation is National Fibromyalgia Association, Newport Beach, California, USA. She declares no conflicts of interest relevant to the article. This correction applies only to the February 15 2024 First Release. The correct author byline and footnotes appear in the print and online issues.","PeriodicalId":501812,"journal":{"name":"The Journal of Rheumatology","volume":"48 18","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-05-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140970437","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-04-15DOI: 10.3899/jrheum.2023-0981
Naomi Schlesinger, Michael H Pillinger, Peter E Lipsky
This report evaluates rheumatologists' stated adherence to and agreement with the 2020 American College of Rheumatology (ACR) Guideline for the Management of Gout.
本报告评估了风湿病学家对 2020 年《美国风湿病学会（ACR）痛风管理指南》的遵守和认同情况。
{"title":"Knowledge of and stated adherence to the 2020 ACR Guideline for Gout Management: Results of a survey of US rheumatologists.","authors":"Naomi Schlesinger, Michael H Pillinger, Peter E Lipsky","doi":"10.3899/jrheum.2023-0981","DOIUrl":"https://doi.org/10.3899/jrheum.2023-0981","url":null,"abstract":"This report evaluates rheumatologists' stated adherence to and agreement with the 2020 American College of Rheumatology (ACR) Guideline for the Management of Gout.","PeriodicalId":501812,"journal":{"name":"The Journal of Rheumatology","volume":"37 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140556983","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Upadacitinib in Rheumatoid Arthritis and Inadequate Response to Conventional Synthetic Disease-Modifying Antirheumatic Drugs: Efficacy and Safety Through 5 Years (SELECT-NEXT).","authors":"Gerd R Burmester, Filip Van den Bosch, John Tesser, Anna Shmagel, Yanxi Liu, Nasser Khan, Heidi S Camp, Alan Kivitz","doi":"10.3899/jrheum.2023-1062","DOIUrl":"https://doi.org/10.3899/jrheum.2023-1062","url":null,"abstract":"To report 5-year efficacy and safety of upadacitinib in rheumatoid arthritis (RA) from the phase 3 long-term extension (LTE) of SELECT-NEXT.","PeriodicalId":501812,"journal":{"name":"The Journal of Rheumatology","volume":"25 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140556788","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-04-15DOI: 10.3899/jrheum.2023-1071
Janet H Roberts, Cheri Gun, Jennifer E Mackinnon, Susan Parlee, Volodko Bakowsky, Trudy Taylor, Claire E H Barber, John G Hanly
Given global shortages in the rheumatology workforce, the demand for rheumatology assessment often exceeds the capacity to provide timely access to care. Accurate triage of patient referrals is important to ensure appropriate utilization of finite resources. We assessed the feasibility of physiotherapist-led triage utilizing a standardized protocol, in identifying cases of inflammatory arthritis (IA), as compared to usual rheumatologist triage of referrals for joint pain, in a tertiary care rheumatology clinic.
{"title":"Feasibility of physiotherapist-led rheumatology triage: A randomized study.","authors":"Janet H Roberts, Cheri Gun, Jennifer E Mackinnon, Susan Parlee, Volodko Bakowsky, Trudy Taylor, Claire E H Barber, John G Hanly","doi":"10.3899/jrheum.2023-1071","DOIUrl":"https://doi.org/10.3899/jrheum.2023-1071","url":null,"abstract":"Given global shortages in the rheumatology workforce, the demand for rheumatology assessment often exceeds the capacity to provide timely access to care. Accurate triage of patient referrals is important to ensure appropriate utilization of finite resources. We assessed the feasibility of physiotherapist-led triage utilizing a standardized protocol, in identifying cases of inflammatory arthritis (IA), as compared to usual rheumatologist triage of referrals for joint pain, in a tertiary care rheumatology clinic.","PeriodicalId":501812,"journal":{"name":"The Journal of Rheumatology","volume":"37 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140556684","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-04-15DOI: 10.3899/jrheum.2024-0321
Marco Di Carlo, Benedetta Bianchi, Fausto Salaffi
The pathophysiological uncertainties in fibromyalgia (FM) mean that its diagnosis, to this day, remains a strictly clinical exercise. The physician's evaluation of symptoms is therefore of fundamental importance both for the correct diagnostic framing of the patient and also for guiding a personalized therapeutic approach.1.
{"title":"Fibromyalgia and the Difficult Synthesis.","authors":"Marco Di Carlo, Benedetta Bianchi, Fausto Salaffi","doi":"10.3899/jrheum.2024-0321","DOIUrl":"https://doi.org/10.3899/jrheum.2024-0321","url":null,"abstract":"The pathophysiological uncertainties in fibromyalgia (FM) mean that its diagnosis, to this day, remains a strictly clinical exercise. The physician's evaluation of symptoms is therefore of fundamental importance both for the correct diagnostic framing of the patient and also for guiding a personalized therapeutic approach.<sup>1</sup>.","PeriodicalId":501812,"journal":{"name":"The Journal of Rheumatology","volume":"37 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140556821","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-04-15DOI: 10.3899/jrheum.2024-0081
Shay Brikman, Reuven Mader, Amir Bieber
Diffuse idiopathic skeletal hyperostosis (DISH) is known to be associated with metabolic syndrome and with obesity in particular. The prevalence of DISH increases with age, with an average of 10% in those aged 70 years and older.
{"title":"High Frequency of Diffuse Idiopathic Skeletal Hyperostosis in Patients With Obesity Hypoventilation Syndrome.","authors":"Shay Brikman, Reuven Mader, Amir Bieber","doi":"10.3899/jrheum.2024-0081","DOIUrl":"https://doi.org/10.3899/jrheum.2024-0081","url":null,"abstract":"Diffuse idiopathic skeletal hyperostosis (DISH) is known to be associated with metabolic syndrome and with obesity in particular. The prevalence of DISH increases with age, with an average of 10% in those aged 70 years and older.","PeriodicalId":501812,"journal":{"name":"The Journal of Rheumatology","volume":"66 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140556764","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-04-15DOI: 10.3899/jrheum.2024-0302
Edward Alveyn, James Galloway, Laura C Coates
In the contemporary healthcare climate, we are acutely aware that our resources are finite. This is particularly pertinent in government-funded healthcare settings, where clinical teams often face the challenge of meeting increasing patient demand with static or dwindling capacity.1-4.
{"title":"Patient-Initiated Follow-Up.","authors":"Edward Alveyn, James Galloway, Laura C Coates","doi":"10.3899/jrheum.2024-0302","DOIUrl":"https://doi.org/10.3899/jrheum.2024-0302","url":null,"abstract":"In the contemporary healthcare climate, we are acutely aware that our resources are finite. This is particularly pertinent in government-funded healthcare settings, where clinical teams often face the challenge of meeting increasing patient demand with static or dwindling capacity.<sup>1-4</sup>.","PeriodicalId":501812,"journal":{"name":"The Journal of Rheumatology","volume":"108 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140556867","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-04-15DOI: 10.3899/jrheum.2023-1214
Dawn M E Bowdish, Vinod Chandran, Carol A Hitchon, Gilaad G Kaplan, J Antonio Avina-Zubieta, Paul R Fortin, Maggie J Larché, Gilles Boire, Anne-Claude Gingras, Roya M Dayam, Ines Colmegna, Luck Lukusa, Jennifer L F Lee, Dawn P Richards, Daniel Pereira, Tania H Watts, Mark S Silverberg, Charles N Bernstein, Diane Lacaille, Jenna Benoit, John Kim, Nadine Lalonde, Janet Gunderson, Hugues Allard-Chamard, Sophie Roux, Joshua Quan, Lindsay Hracs, Elizabeth Turnbull, Valeria Valerio, Sasha Bernatsky
To determine how serologic responses to COVID vaccination/infection in immunemediated inflammatory disease (IMID) are affected by time since last vaccination and other factors.
{"title":"When Should I Get My Next COVID Vaccine? Data from the SUrveillance of responses to COVID-19 vaCcines in systEmic immunE mediated inflammatory Diseases (SUCCEED)study.","authors":"Dawn M E Bowdish, Vinod Chandran, Carol A Hitchon, Gilaad G Kaplan, J Antonio Avina-Zubieta, Paul R Fortin, Maggie J Larché, Gilles Boire, Anne-Claude Gingras, Roya M Dayam, Ines Colmegna, Luck Lukusa, Jennifer L F Lee, Dawn P Richards, Daniel Pereira, Tania H Watts, Mark S Silverberg, Charles N Bernstein, Diane Lacaille, Jenna Benoit, John Kim, Nadine Lalonde, Janet Gunderson, Hugues Allard-Chamard, Sophie Roux, Joshua Quan, Lindsay Hracs, Elizabeth Turnbull, Valeria Valerio, Sasha Bernatsky","doi":"10.3899/jrheum.2023-1214","DOIUrl":"https://doi.org/10.3899/jrheum.2023-1214","url":null,"abstract":"To determine how serologic responses to COVID vaccination/infection in immunemediated inflammatory disease (IMID) are affected by time since last vaccination and other factors.","PeriodicalId":501812,"journal":{"name":"The Journal of Rheumatology","volume":"42 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140556648","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：